Remarkably, it has been found by our group that the interaction between OXA and endocannabinoids participates in the molecular process leading to the phosphorylation of Tau at the threonine 231 residue (pT231-Tau) (Forte et al. 2022), a sensitive and specific early marker for AD diagnosis. Here, MAPT is linked to Alzheimer disease.